171 related articles for article (PubMed ID: 24467642)
1. Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE.
Ryan R; Dayaram YK; Schaible D; Coate B; Anderson D
Curr HIV Res; 2013 Oct; 11(7):570-5. PubMed ID: 24467642
[TBL] [Abstract][Full Text] [Related]
2. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
[TBL] [Abstract][Full Text] [Related]
4. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
[TBL] [Abstract][Full Text] [Related]
5. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
Cohen CJ; Molina JM; Cassetti I; Chetchotisakd P; Lazzarin A; Orkin C; Rhame F; Stellbrink HJ; Li T; Crauwels H; Rimsky L; Vanveggel S; Williams P; Boven K;
AIDS; 2013 Mar; 27(6):939-950. PubMed ID: 23211772
[TBL] [Abstract][Full Text] [Related]
6. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
Wohl DA; Orkin C; Doroana M; Pilotto JH; Sungkanuparph S; Yeni P; Vanveggel S; Deckx H; Boven K
Antivir Ther; 2014; 19(2):191-200. PubMed ID: 24430534
[TBL] [Abstract][Full Text] [Related]
7. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
8. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
9. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Hodder S; Arasteh K; De Wet J; Gathe J; Gold J; Kumar P; Mohapi L; Short W; Crauwels H; Vanveggel S; Boven K
HIV Med; 2012 Aug; 13(7):406-15. PubMed ID: 22416849
[TBL] [Abstract][Full Text] [Related]
10. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
Molina JM; Clumeck N; Redant K; Rimsky L; Vanveggel S; Stevens M;
AIDS; 2013 Mar; 27(6):889-897. PubMed ID: 23276806
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
12. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
13. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
14. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
16. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M; Amaya G; Clumeck N; Arns da Cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A; Vanveggel S; Boven K;
J Antimicrob Chemother; 2012 Aug; 67(8):2020-8. PubMed ID: 22532465
[TBL] [Abstract][Full Text] [Related]
18. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
[TBL] [Abstract][Full Text] [Related]
20. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
